PDT Partners’s ARS Pharmaceuticals SPRY Stock Holding History

PDT Partners’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-16,881	Closed	-$112K	–	1099
2021 Q4	$112K	Buy	16,881 +1,289	+8%	+$10.5K	0.01%	814
2021 Q3	$156K	Buy	+15,592	New	+$385K	0.01%	710

Other funds holding SPRY

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PDT Partners's SPRY Position: Q1 2022 in Review

PDT Partners sold out of ARS Pharmaceuticals (SPRY) in Q1 2022, closing a stake of 16,881 shares — an estimated $112K sold.

PDT Partners first reported a position in SPRY in Q3 2021 and held it in 2 quarters. The position peaked at $156K in Q3 2021. 70 funds tracked by Wall St. Rank hold SPRY as of Q1 2022.

PDT Partners reported no remaining ARS Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
PDT Partners sold 16,881 ARS Pharmaceuticals shares in Q1 2022, an estimated $112K.
PDT Partners first reported a position in ARS Pharmaceuticals in Q3 2021 and held it in 2 quarters.
PDT Partners's ARS Pharmaceuticals position peaked at $156K in Q3 2021.
70 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2022.

Based on PDT Partners's 13F filing for Q1 2022, filed 16 May 2022.